ITPA and anemia (phenotype): Because reduced ITPase activity results in improved outcomes for patients undergoing ribavirin treatment [52], it is plausible that competitive ITPase inhibitors could be developed to help reduce anemia in individuals not affected by ITPA polymorphism.